InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,422.43
(
1.46%
)
US TECH 100
18,464.00
(
2.26%
)
Dow Jones
39,691.12
(
0.85%
)
Brent Oil
80.40
(
-1.48%
)
Bitcoin
61,016.35
(
2.80%
)
Post# of 252870
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120264
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 141116

Tuesday, 07/24/2012 10:50:11 AM

Tuesday, July 24, 2012 10:50:11 AM

Post# of 252870
2Q12 US Tysabri sales were $211M (+15% YoY, +5% QoQ), about 1/3 as much as US sales of Copaxone:

http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1717583

Teva will report 2Q12 US sales of Copaxone on 8/2/12.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up